LoQus23 Therapeutics
Generated by Meeveem AI
"Developing small molecule therapies to stop DNA instability in Huntington's Disease"
Cambridge
•1 - 10 Employees
•Biotechnology
About LoQus23 Therapeutics
LoQus23 develops oral small molecule drugs that target the root cause of Huntington's Disease and other triplet repeat expansion disorders. By blocking the DNA mismatch repair pathway that drives somatic expansion, the company's lead programme aims to halt the progressive DNA instability that causes neurodegeneration in these inherited diseases. Founded in 2019 by experts in Huntington's research and drug discovery, LoQus23 combines structure-based drug design with deep mechanistic understanding. The first candidate, LQT-23, is an allosteric inhibitor of MutSβ set to enter clinical trials in 2026, offering new hope to patients with conditions that currently have no disease-modifying treatments.
9
Team Members
2019
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A world where triplet repeat expansion diseases no longer progress, where DNA instability can be stopped and patients live full lives without the shadow of neurodegeneration.
Our Mission
At LoQus23, our mission is to develop transformative oral small molecule therapies that stop DNA instability and slow neurodegeneration for patients with Huntington's disease and other triplet repeat expansion diseases.